MedySapiens initiates global expansion with deals in Taiwan
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Kang explained that services that are limited to the Korean market are "insufficient" because the company believes securing a wider range of rare disease genomic data is necessary to "meet the urgent needs of healthcare professionals and parents of ill children".
Kang noted that the company observed great interest and expectation for the rare disease data accumulated within Korea and the AI diagnostic solution, adding that the company will continue to expand to other continents. " Once we confirm the clinical effectiveness in Taiwan and the United States, we plan to expand our services to countries that are considering support for rare disease patients, including Europe and the Middle East."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
“We were selected for a program jointly organized by Taipei Medical University (TMU) and a local accelerator and will receive specimens to evaluate newborns at high risk for rare diseases,” MedySapiens’ Kang Sanggoo said.
Kang explained that services that are limited to the Korean market are “insufficient” because the company believes securing a wider range of rare disease genomic data is necessary to “meet the urgent needs of healthcare professionals and parents of ill children”.
MedySapiens has been developing diagnostic systems in collaboration with major Korean hospitals as it5 aims to minimize the newborns’ physical pain as well as ensuring that medical treatment is provided at the optimal time. The company developed a technology that simultaneously and accurately tests for 220 rare diseases using a small amount of blood in a comparatively short time.
The company decided to actively engage in securing multiethnic genomic data for rare diseases from 2024 onwards. Although clinical experience is critical to diagnosis, rare diseases are often difficult to diagnose accurately due to their low prevalence.
But MedySapiens can now access data from six TMU-affiliated hospitals via the “TMU X BE Cohort & Accelerating” program jointly supported by TMU and Taiwanese medical technology company BE Accelerator. Taiwan is known to have almost ten times more rare disease patients per capita than Korea, and MedySapiens expects its Taiwanese partnerships will be the first step towards potential expansion into the wider Asia-Pacific market. The company has agreed to secure approximately 200 samples per year starting in May 2024 and is currently in the middle of Institutional Review Board (IRB) approval procedures.
The Korean company participated in the government‘s economic mission to the United States in early April 2023, where it signed a memorandum of understanding to establish a joint venture with Sharp Hospital, one of the West Coast’s largest hospitals. The company has now formed a U.S. subsidiary and is in the process of opening a laboratory as well as obtaining IRB approval within the hospital.
Kang noted that the company observed great interest and expectation for the rare disease data accumulated within Korea and the AI diagnostic solution, adding that the company will continue to expand to other continents. “ Once we confirm the clinical effectiveness in Taiwan and the United States, we plan to expand our services to countries that are considering support for rare disease patients, including Europe and the Middle East.”
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- 尹 '모든 국민 25만원 지원금' 거절 李 '여야정 협의체 추가논의' 거부 - 매일경제
- ‘1살 아기’ 승객 대신 ‘101세 할머니’가 왜…항공사 직원들 ‘화들짝’ - 매일경제
- “이 제품 절대 먹지 마세요” 베트남산 냉동새우살서 식중독균 검출 - 매일경제
- 이번엔 3억 로또 아파트 뜬다…39평 5억원대 2가구, 어딘가 봤더니 - 매일경제
- 연예인 맛집이라며…15만원짜리 삼겹살 보니 “불판 닦는 비계만 가득” - 매일경제
- 양복 입고 관악산 오르던 중년男…희망의 끈 끊어버린 野가맹사업법 [기자24시] - 매일경제
- “잠자던 20대여성, 갑자기 옷 찢더니”...수면중 무의식 성행위, 희귀 수면장애라는데 - 매일경
- “돈 많은 것도 부러운데”…부자들 40% 이상 매일 ‘이것’ 한다 - 매일경제
- 한달새 5억 쑥…한강변 아파트 신고가 행진 - 매일경제
- ‘황선홍호 격파’ 신태용 감독의 인니, 우즈벡에 0-2 완패…결승행 좌절 → 3·4위전서 파리행 노